Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: Relationship to dose, antihistamine pretreatment, and infusion number
Academic Article
Overview
MeSH Major
Antibodies, Monoclonal
Antirheumatic Agents
Arthritis, Rheumatoid
Diphenhydramine
Histamine H1 Antagonists
Hypersensitivity
abstract
Infusion-related reactions to infliximab were infrequent, rarely severe, and easily manageable. The frequency of reactions was equivalent in patients treated with 3 mg/kg compared to 5 mg/kg. Reactions were significantly more frequent in infusions where patients were pretreated with the antihistamine diphenhydramine, compared to those not involving pretreatment.
